Obesity is characterized by excessive accumulation of lipid metabolites in adipose tissues as well as in nonadipose tissues, such as liver, muscle, and pancreas ( 1 ). Because obesity is considered as a major risk factor for most metabolic diseases, including hyperlipidemia, hypercholesterolemia, type 2 diabetes, hypertension, and cardiovascular disease ( 2-4 ), numerous investigations have been conducted to elucidate the key components in energy homeostasis, which is crucial to develop therapeutic agents for obesity and obesity-associated metabolic disorders.
A subset of mice from each group (n = 6/group) was subjected to cold exposure at 4°C, and rectal temperature was monitored for 4 h to determine changes in the core body temperature.
Biochemical analysis
The levels of plasma triglycerides, free fatty acids, and total cholesterol were measured using Infi nity reagents (Thermo, Melbourne, Australia). LDL cholesterol levels were determined as previously described ( 30 ) . Plasma insulin (Mercodia, Uppsala, Sweden) and adiponectin (Adipogen, Incheon, Korea) levels were quantifi ed by an ELISA kit, according to the manufacturer's instructions. Hepatotoxicity was determined by measuring plasma alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels ( 30 ) .
Histological analysis
Tissue sections were prepared as described previously ( 29 ) . Briefl y, dissected samples were mounted on glass slides and fi xed. The epididymal WAT and liver samples were then stained with perilipin and hematoxylin and eosin (H and E), respectively. Images were taken at the magnifi cation indicated in the fi gures.
Culture and adenoviral infection
Myocytes (C 2 C 12 ) and hepatoma cells (FAO) were grown in DMEM (Hyclone, Logan, UT) supplemented with 10% fetal bovine serum (FBS), 100 units/ml penicillin, and 100 mg/ml streptomycin. Cells were maintained at 37°C in a humidifi ed atmosphere containing 5% CO 2 . The C 2 C 12 cells were differentiated as described previously ( 38 ) . Briefl y, confl uent C 2 C 12 cells were incubated with DMEM supplemented with 2% horse serum for 6-7 days. The medium was changed daily during myocyte differentiation.
For viral infection, differentiated C 2 C 12 cells were incubated with adenovirus expressing null or dominant negative-AMPK ␣ 2 ( T172A ) (10 plaque formation units/cell) in serum-free DMEM for 3 h. The medium was then replaced with fresh DMEM containing 10% FBS for 16 h. Cells were then subjected to experimental treatments .
Quantitative real-time RT-PCR analysis
Total RNA was isolated from liver, muscle, and epididymal fat tissues as described previously ( 39 ) , and cDNA was synthesized using the M-MuLV reverse transcriptase kit (Fermentas, Glen Burnie, MD). The primers used for the real-time PCR analyses were produced by Bioneer (Korea), and the primer sequences are provided in supplementary Table I .
Western blotting
Western blotting was performed as previously described, with minor modifi cations ( 40 ) . An equal amount of protein from each sample was separated on 8% or 10% SDS-PAGE gels and transferred to nitrocellulose membranes. Blots were blocked with 5% nonfat milk in TBS containing 0.1% Tween-20 (TBST) at room temperature for 1 h, and then incubated overnight at 4°C with specifi c antibodies as follows: AMPK (Cell Signaling Danver, MA), phosphoAMPK (Thr 172 ) (Cell Signaling), acetylCoA carboxylase (Upstate), phosphoACC (Ser 79 ) (Upstate), and GAPDH (Ab Frontier, Korea). After washing three times with TBST, the blots were hybridized with secondary antibodies conjugated to horseradish peroxidase. Immunoreactive signals were detected using a LuminoImager (LAS-3000) and Science Lab 2001 Image Gauge software (Fuji Photo Film, Tokyo, Japan).
Fatty acid oxidation
Fatty acid oxidation was measured as previously described, with minor modifi cations ( 38 ) . C 2 C 12 cells and FAO cells were an allosteric inhibitor of carnitine palmitoyltransferase (CPT); this, in turn, results in fatty acid oxidation by accelerating CPT-mediated fatty acid translocation into mitochondria (11) (12) (13) . Moreover, activated AMPK increases mitochondrial activity and biogenesis in muscle (14) (15) (16) (17) . In accordance with these data, whole-body and liver-specifi c AMPK ␣ 2 knockout mice exhibit increased plasma triglyceride levels ( 18, 19 ) . Recently, it has been reported that AMPK is involved in NAD-dependent deacetylase sirtuin-1 (SIRT1)-dependent metabolic regulation (20) (21) (22) (23) . Thus, it has been proposed that AMPK is a key target for treating obesity and metabolic disorders ( 6 ) .
Recent studies have demonstrated that various bioactive chemicals, such as metformin, phenformin, thiazolidinediones, quercetin, resveratrol, and berberine, act as AMPK activators and exhibit benefi cial effects on metabolic disorders, including obesity, hyperlipidemia, and insulin resistance (24) (25) (26) (27) (28) (29) (30) . In this study, we have investigated whether glabridin, a key chemical of major isofl avans from licorice extracts, might regulate AMPK activity, leading to antiobesity or antidiabetic effects in obese animals. Although it has been previously reported that licorice extracts show metabolically benefi cial effects, including anti-atherosclerosis and body weight control, its underlying mechanisms are not clearly understood (31) (32) (33) (34) (35) (36) (37) . Moreover, it is unknown which single chemical in licorice extracts would mediate such effects. In several obese rodent models, we observed that glabridin decreases adiposity and ameliorates lipid dysregulation as well as insulin resistance. More importantly, we discovered that glabridin stimulates AMPK activity through the regulation of mitochondrial activity. Taken together, these results suggest that glabridin would be an effective AMPK activator having therapeutic potency for obesity-related metabolic diseases.
MATERIALS AND METHODS

Animal care and experimental protocol
Mice (C57BL/6J strain) were maintained according to the guidelines of the Seoul National University Animal Experiment Ethics Committee. They were housed in solid-bottom cages with wood shavings for bedding in a room maintained at 25°C with a 12:12 h light:dark cycle (lights on at 0700 h). The mice were fed a nonpurifi ed diet until they were assigned to an experimental protocol. To induce obesity, mice were given a high-fat diet (HFD; 45% of calories derived from fat; Research Diets Inc., New Brunswick, NJ) for 12 weeks, and HFD-induced obese mice were then orally administered with vehicle (0.1% sodium lauryl sulfate) or glabridin (Mazence Inc, Suwon, Korea) at a dose of 150 mg/kg/day for 4 weeks. Body weight and food intake were measured daily during the experimental protocol. At the end of the experimental period, one mouse from each group was anesthetized, and the distribution of body fat was examined by magnetic resonance imaging (MRI). All other mice were euthanized, and dissected tissue specimens were immediately stored at Ϫ 80°C until analysis.
For the intraperitoneal glucose tolerance test (IPGTT), fasted mice were injected with glucose (2 g/kg). Blood glucose levels were measured at the indicated time points with a freestyle blood glucose meter (Therasense; Uppsala, Sweden). with Inno C18 column (5.0 m, 4.6 × 150 mm). The mobile phase consisted of 0.02 M KH 2 PO 4 (pH 6.0) in water (A) and 0.02 M KH 2 PO 4 in 10% methanol (B). The optimal mobile phase was set as follows: 0-15 min, 100% A; 15-18 min, gradient to A/B = 5:95; 18-30 min, 100% B; 30-40 min 100% A; the fl ow rate and the wavelength were set at 0.7 ml/min and 254 nm. ATP and AMP appeared at 11.3 and 24.3 min, respectively.
Statistical analysis
Error bars represent standard errors, and P values are calculated from Student t -test. P < 0.05 was interpreted as statistically signifi cant.
RESULTS
Glabridin reduces body weight in obese animals
To investigate the effects of glabridin on body weight change, glabridin was administered to high-fat diet (HFD)-fed obese mice ( Fig. 1A ) . Glabridin gradually reduced body weight in HFD-fed obese mice ( Fig. 1B, C ) . Glabridin also decreased body weight in leptin-defi cient Lep ob / Lep ob mice (supplementary Fig. I-A) . Interestingly, g labridin incubated with medium containing 0.1 mmol/l palmitate (9,10-[ 3 H]palmitate, 5 Ci/ml; PerkinElmer Life, Boston, MA) and 1% BSA. After 24 h of incubation, the medium was precipitated with an equal volume of 10% trichloroacetic acid (Sigma), vigorously mixed, and centrifuged at 4°C for 10 min. The supernatants were transferred to capless 1.5 ml microcentrifuge tubes placed in a scintillation vial containing 0.5 ml unlabeled water, and incubated at 55°C overnight. The tubes were then removed, and the 3 H 2 O content was measured in a scintillation counter.
Measurement of AMPK activity
AMPK activity was measured by detection of phosphorylation of SAMS peptide (HMRSAMSGLHLVKRR) as previously described, with minor modifi cations ( 24 ) . Cell lysates were prepared with digitonin buffer (50 mM Tris-HCl, pH 7.5, 1 mM EDTA, 0.25% sucrose, 0.4 mg/ml digitonin, 1.5 mM PMSF), followed by precipitation with 35% saturated ammonium sulfate. Samples were suspended with assay buffer, and the reaction was . The reactions were terminated by spotting on P-81 phosphocellulose paper, washing three times in 1% phosphoric acid and once with acetone, and air-drying. AMPK activity was determined by measuring the incorporation of 32 P using scintillation counting.
Mitochondrial ATP production rate and activities of complexes I and II
Mitochondria were isolated from the cells, and ATP production rate (APR) was determined as previously described, with minor modifi cations ( 41 ) . Isolated mitochondria (10 g) were suspended in reaction buffer A (0.1% BSA, 150 mM KCl, 0.1 mM MgCl 2 , 25 mM Tris-HCl, 10 mM potassium phosphate, pH 7.4) containing 160 M diadenosine pentaphosphate, 1 mM pyruvate, 100 M ADP, and either 5 mM glutamate/malate or 5 mM succinate. To determine APR, luciferase assays were performed by addition of buffer B (500 mM Tris-acetate, pH 7.75) containing 20 g/ml luciferase (Invitrogen) and 0.8 mM D -luciferin (Invitrogen). The light emission was monitored using a luminometer (20/20 n ; Turner Biosystems, Sunnyvale, CA) at 10 s intervals for 5 min. A standard curve for luminescence was obtained using different concentrations of ATP solution.
Mitochondrial complex I and II activities were assessed using decylubiquinone and dichloroindophenol (DCIP), as described previously ( 42 ) . Briefl y, 10 g of the isolated mitochondrial fractions was preincubated in the appropriate reaction buffer [complex I buffer (70 M decylubiquinone, 60 M DCIP, 1 M antimycin A, 0.35% BSA, 25 mM potassium phosphate, pH 7.4); complex II buffer (70 M decylubiquinone, 60 M DCIP, 1 M antimycin A, 50 M rotenone, 500 M EDTA, 200 M ATP, 0.1% BSA, 80 mM potassium phosphate, pH 7.4)] at 37°C. The reaction was initiated by addition of substrates (complex I: 5 mM glutamate/malate, and complex II: 5 mM succinate and 300 M potassium cyanide) to the mixture, and absorbance was read at 600 nm for 5 min at 20 s intervals. For measurement of the activity of complex I, rotenone (1 M) was added to the reaction mixture, and absorbance was read at 20 s intervals for 5 min.
Adenine nucleotide extraction and measurement
ATP and AMP contents in FAO cells and liver tissues were measured by using high-performance liquid chromatography (HPLC) as previously described, with minor modifi cations ( 43 ) . Briefl y, FAO cells and liver tissues were lysed with 10% percholic acid and neutralized with 5 N KOH. HPLC analysis was performed by DIONEX Ultimate 3000 HPLC system (Thermo, CA) Fig. 1 . Glabridin decreases body weight and food intake in obese mice. A: Structure of glabridin. Glabridin is one of the major fl avonoids in the hydrophobic fraction of G. glabra extract. B-E: HFDfed obese mice (n = 7-8 per group) were orally administered with vehicle or glabridin (150 mg/kg) or used for pair-feeding, for four weeks. B: Gross images of whole body (top) and abdominal fat (bottom) of mice in each group. C, D: Body weight and food consumption were measured every day throughout the experimental period. E: Body temperature during 4 h of cold exposure (n = 6 per group) was measured at indicated time points. Data represent mean ± SE. * P < 0.05 versus vehicle; ** P < 0.01 versus vehicle; # P < 0.05 versus pair-feeding (Student t-test). Each experiment was independently performed at least twice. decreased fat cell size determined by perilipin staining, whereas there was no signifi cant alteration in adipogenesis and expression of adipogenic genes ( Fig. 2C, D and supplementary Fig. III) . Hypertrophic adipocytes are closely associated with increased chronic and low-grade infl ammatory responses in obesity ( 44 ) . To test the idea that glabridin-dependant reduction in fat mass might affect proinfl ammatory responses in the fat tissue of obese animals, gene expression was analyzed. As shown in Fig. 2E , glabridin suppressed the expression of proinfl ammatory genes, such as mcp-1 and inos , in adipose tissues of obese animals, which is correlated with decreased hypertrophic adiposity. In accordance with these results, we also observed that glabridin repressed tumor necrosis factor (TNF) ␣ -mediated proinfl ammatory responses in 3T3-L1 adipocytes (supplementary Fig. IV) .
Because obesity is often accompanied by the development of fatty liver, we examined the liver histology of obese mice in the absence or presence of glabridin administration. Glabridin clearly alleviated fatty liver, as evaluated by macroscopic and microscopic examinations, accompanied with decrease in liver tissue weight ( Fig. 3A , B and supplementary Fig. II) . Furthermore, glabridin signifi cantly decreased the levels of plasma triglycerides, total cholesterol, and LDL cholesterol ( Fig. 3C ) , which are closely associated suppressed food intake ( Fig. 1D and supplementary Fig.  I-B) , which directly contributes to body weight loss. To examine whether the glabridin-induced anti-obesity effect mainly resulted from decreased food intake, pair-feeding tests were conducted. As shown in Fig. 1C , glabridintreated mice clearly showed a greater reduction in body weight than their pair-fed counterparts. In accordance with these data, glabridin slightly, but substantially, elevated body temperature ( Fig. 1E ) , implying that glabridin might stimulate energy expenditure in obese animals. These results suggest that glabridin exerts an anti-obesity effect by enhancing energy expenditure and decreasing food intake.
Glabridin attenuates adiposity, infl ammation, and fatty liver in obese mice
In obese mice, glabridin greatly decreased the size of epididymal and retroperitoneal adipose tissue masses ( Fig. 2A ) . As shown in coronal and transverse MRI sections, the fat contents of visceral and subcutaneous adipose tissues were evidently diminished in glabridin-treated obese animals ( Fig. 2B ) . However, glabridin did not cause signifi cant changes in the weights of the other organs, such as heart, muscle, lung, kidney, and spleen (supplementary Fig. II) . Consistent with fat mass reduction, glabridin 
reduced hepatic and plasma lipid content upon glabridin administration in obese animals, expression of lipogenic genes ( srebp-1c , fas, acc , and scd-1 ) in adipose tissue and liver was downregulated by glabridin ( Fig. 5A , B ) . Conversely, in muscle, the expression of genes for fatty acid oxidation (i.e., cpt1 and aco ) and mitochondrial biogenesis (i.e., nrf and cytc ) was stimulated by glabridin ( Fig. 5C ) . Moreover, glabridin showed a tendency to suppress expression of gluconeogenic genes ( pepck and g6pase ) in the liver of obese animals ( Fig. 5D ). These data indicate that glabridin might alleviate HFD-induced metabolic abnormalities, at least in part, through regulating the expression of a certain set of metabolic genes.
Glabridin stimulates AMPK phosphorylation
AMPK is able to dissipate excessively stored energy by stimulating fatty acid oxidation. To test whether glabridin could potentiate AMPK activity, the levels of AMPK and ACC phosphorylation were examined. In the muscle, liver, and adipose tissue of obese mice, glabridin promoted phosphorylation of AMPK and ACC ( Fig. 6A -C ) . Next, to confi rm whether glabridin could indeed activate AMPK, glabridin was tested in various cell lines. In adipocytes (3T3-L1), hepatoma cells (FAO), myotubes (C 2 C 12 ), and human embryonic kidney cells (HEK 293), glabridin stimulated AMPK phosphorylation in a dose-and time-dependent manner ( Fig. 6D, E and  supplementary Fig. VI) . These data clearly indicate that glabridin is a potent activator of AMPK, which results in its benefi cial effects on glucose and lipid metabolism.
Glabridin promotes fatty acid oxidation through AMPK activation
It has been well established that activated AMPK stimulates fatty acid oxidation and fat assimilation (11) (12) (13) . To with fatty liver in obesity. Simultaneously, glabridin exhibited a tendency to reduce plasma levels of ALT and AST in HFD-fed obese mice ( Fig. 3D ) , implying that hepatic dysfunction in obesity would be relieved by glabridin.
Glabridin improves hyperinsulinemia and glucose metabolism
As obesity is one of the key risk factors for insulin resistance as well as type 2 diabetes, the effects of glabridin on glucose and insulin sensitivity were tested. In HFD-fed obese mice, glabridin barely changed basal glucose levels ( Fig. 4A ) . However, in the presence of glabridin, the plasma level of insulin markedly decreased, whereas adiponectin levels increased ( Fig. 4B, C ) , which seemed to be associated with reduced adiposity and plasma lipid metabolites. Moreover, glabridin signifi cantly relieved glucose intolerance and insulin sensitivity in HFD-fed obese mice ( Fig. 4D ) . Consistently, in obese Zucker fa/fa rats, glabridin ameliorated glucose intolerance and insulin sensitivity (supplementary Fig. V-A, B) . Together, these results clearly indicate that glabridin could improve insulin sensitivity and glucose metabolism in obese and/or diabetic animals.
Glabridin regulates metabolic gene expression in fat, liver, and muscle
To better understand the molecular mechanism(s) by which glabridin mediates the benefi cial effects on obese animals described above, the expression of genes involved in energy metabolism was investigated. Consistent with the to berberine, glabridin treatment for 12 h signifi cantly elevated cellular AMP level, leading to increase in AMP/ATP ratio by 52.6% ( Fig. 8F ) . Consistently, AMP/ATP ratio in the liver of glabridin-treated obese mice was also slightly, but substantially, increased ( Fig. 8G ). These data suggest that glabridin is able to activate AMPK by reducing mitochondrial ATP production like other AMPK activators, including metformin and berberine.
DISCUSSION
Various phytochemicals used to treat metabolic diseases are often able to stimulate AMPK activity (24) (25) (26) (27) (28) (29) (30) . In this study, we present data indicating that glabridin could alleviate body weight, adiposity, fatty liver, and hyperlipidemia by activation of AMPK, which would lead to the improvement of glucose and lipid homeostasis. Previous studies have demonstrated that licorice fl avonoid oil containing glabridin decreases visceral adiposity, hyperglycemia, and hepatic lipogenesis (34) (35) (36) (37) . However, biological pathways, as well as molecular mechanisms to mediate the benefi cial effects of glabridin on whole-body energy homeostasis, have not been elucidated.
In peripheral tissues, AMPK activation facilitates lipid dissipation via stimulation of fatty acid oxidation ( 6 ) . Upon activation of AMPK, fatty acid oxidation is augmented by rapid ACC phosphorylation and is further sustained by expression of certain genes involved in fatty acid oxidation. In this study, we observed that glabridin promoted AMPK activation and stimulated fatty acid oxidation, suggesting that upregulation of fatty acid oxidation via activation of AMPK is the key mechanism for the benefi cial effects of glabridin. This speculation was further supported by the observations that ComC treatment or DN-AMPK overexpression decreased the effects of glabridin on fatty acid oxidation. For sustainable and chronic fat burning, glabridin also affects lipid homeostasis by regulation of gene expression. In muscle, glabridin stimulated the expression of a set of genes associated with fatty acid test whether glabridin promotes fat burning via AMPK, the effect of glabridin on fatty acid oxidation was examined. As expected, glabridin signifi cantly enhanced fatty acid oxidation in both C 2 C 12 and FAO cells ( Fig. 7A , B ) . To verify whether the increased fatty acid oxidation with glabridin requires AMPK, AMPK activity was repressed by either ComC, a well-known AMPK inhibitor, or dominant negative (DN) AMPK. In C 2 C 12 cells, glabridin-induced AMPK activation, ACC phosphorylation, and fatty acid oxidation were attenuated by either ComC or DN-AMPK ( Fig.  7C-F ) . These data suggest that glabridin can promote fatty acid oxidation through AMPK activation, leading to the dissipation of excessively stored energy sources in obese animals.
Glabridin affects mitochondrial functions and cellular AMP/ATP ratio
Consistent with the results for AMPK activation, glabridin signifi cantly increased AMPK activity in FAO cells ( Fig. 8A ) . However, glabridin failed to directly stimulate AMPK activity, unlike AMP (supplementary Fig. VIII-A) . Also, it is likely that CaMKK ␤ and LKB were not key players in glabridin-induced AMPK phosphorylation (supplementary Fig. VIII-B, C) . To decipher the mechanism(s) underlying AMPK activation by glabridin, we tested mitochondrial activities in the absence or presence of glabridin. As shown in Fig. 8B , C , glabridin decreased the ATP production rate by about 15% in the presence of glutamate/malate or succinate, which are the best-known electron donors in mitochondria. As a positive control, berberine, another well-characterized AMPK activator, was used to validate the change in mitochondrial function ( 45 ) . In addition, in comparison with the vehicle, glabridin signifi cantly reduced the activities of mitochondrial electron transport chain (ETC) complexes I and II ( Fig.  8D, E ) . To verify whether mitochondrial function attenuated by glabridin is associated with change of AMP/ATP ratio, cellular adenine nucleotide contents were measured in FAO cells with or without glabridin or berberine. Similar hand, as a metabolic adaptation to fasting in muscle, AMPK promotes SIRT1 activity by increasing the cellular levels of NAD + and triggers SIRT1-dependent deacetylation of PCG1 ␣ and FOXO1, resulting in induction of expression of the genes involved in mitochondrial and fatty acid metabolism ( 20-23, 48, 49 ) . Thus, it is plausible that glabridin-stimulated AMPK activation alters the expression of genes involved in lipid metabolism, which might chronically ameliorate lipid dysregulation in obese animals.
Accumulating evidence has demonstrated the critical roles of hypothalamic AMPK in the regulation of feeding behavior and energy homeostasis ( 30, (50) (51) (52) . In the hypothalamus, decreased phosphorylation of AMPK and ACC induces anorexic effects ( 51, 52 ) . Interestingly, this hypothalamic AMPK regulation is also transmitted via neuronal signals to peripheral tissues, such as skeletal muscle, and thereby rapidly potentiates fatty acid oxidation, leading to dissipation of excess lipid ( 30, 53, 54 ) . In this study, we oxidation. Conversely, glabridin reduced expression of lipogenic genes in liver and adipose tissue, eventually leading to the suppression of unnecessary de novo lipogenesis. Although details of the mechanism by which glabridin infl uences expression of these genes remain to be elucidated, previous reports have shown that AMPK activation upon treatment with metformin, berberine, or AICAR, which are well-characterized AMPK activators, also controls expression of those genes ( 15-17, 24, 29, 30 ) . Recently, several reports have shed light on the connection between AMPK and SIRT1 in the regulation of energy homeostasis ( 20-23, 46, 47 ) . For instance, in liver, SIRT1 activates AMPK activity and reduces expression of fas, leading to diminished lipid accumulation ( 46, 47 ) . On the other conversion into ZMP, an AMP mimetic ( 55 ) . On the other hand, several antidiabetic drugs, including thiazolidinediones, metformin, and berberine, activate AMPK by changing mitochondrial activity ( 45, (56) (57) (58) . Although the mechanism(s) by which glabridin might change LKB1 or CAMKK ␤ needs to be further investigated, we obtained some clues that glabridin would activate AMPK independent of CAMKK ␤ -or LKB-activation. Rather, we observed that glabridin evidently attenuated mitochondrial ATP production and suppressed ETC complex I and II activities, accompanied with elevation of cellular AMP contents and AMP/ATP ratio. Thus, these data imply that increase observed that glabridin exhibited an anorexic effect and promoted fatty acid oxidation. Although it is currently unresolved whether glabridin might affect the central nervous system to regulate whole-body energy homeostasis, we cannot rule out the possibility that glabridin may modulate hypothalamic AMPK activity, which might infl uence food intake and peripheral fatty acid oxidation. Depending on the signaling cues, AMPK activation is mediated by several different mechanisms, such as changes of AMP/ATP ratio, intracellular Ca 2+ , and activities of AMPK upstream kinases ( 45 ) . For instance, AICAR, a well-known AMPK activator, directly binds to AMPK after intracellular in cellular AMP/ATP ratio by glabridin would be the major molecular mechanism responsible for AMPK activation.
Glabridin effi ciently reduces adipose mass and adipocyte hypertrophy in obese animals. Although it has been demonstrated that AMPK activation with berberine potently inhibits adipogenesis and lipogenesis ( 29 ) , glabridin did not signifi cantly affect adipogenesis. Consistently, in adipose tissue, expression of adipogenic genes, including ppar ␥ and aP 2, was not changed by glabridin. However, the expression of lipogenic genes was potently suppressed in adipose tissue of glabridin-treated obese mice, which is similar to the fi ndings obtained for berberine or metformin ( 24, 29, 30 ) . Thus, it is very likely that glabridin reduces lipogenesis, but not adipogenesis, via AMPK activation, which might contribute to reduced adipose tissue mass and adipocyte hypertrophy.
In macrophages, AMPK activation relieves lipopolysaccharide-induced infl ammation ( 59 ) . Similarly, glabridin decreased proinfl ammatory gene expression in adipose tissues. In differentiated adipocytes, glabridin stimulated AMPK phosphorylation and decreased expression of proinfl ammatory genes in the presence of TNF ␣ , a potent infl ammatory inducer. Consistent with these data, glabridin exhibits anti-infl ammatory responses in colitic subjects ( 60 ) . Therefore, it appears that glabridin-induced AMPK might also contribute to the suppression of infl ammatory responses, which would lead to improvements in metabolic disorders, such as insulin resistance in obesity.
In conclusion, glabridin, a novel AMPK activator, ameliorates adiposity and metabolic disorders in obese animals. These effects of glabridin are produced through strong and sustained changes in metabolic regulation that facilitate catabolism of fuel storage, implying that glabridin would be a potential candidate for treatment of obesity and metabolic disorders.
